The way nephrology develops in the new millennium is bound to be affected by changes in the nephrologist’s clinical environment, as well as by the progress made in basic research which will need to find a clinical application. The nephrologist can expect to be more and more involved in renal substitution therapy, not just providing the treatment, but also managing the cost of the service. In the field of nephropathology, the highest expectations surround molecular biology and its application to both acquired and hereditary renal disease; the goal is to find an outlet for gene therapy in clinical practice. Artificial substitution therapy will focus chiefly on the project of ‘intelligent dialysis’, whereby biological and diagnostic components are combined according the specific needs of the individual patient. The ideal scenario for renal transplantation in the coming millennium would be one where donor supply matches the demand (xenotransplant?), where immunomodulation is perfected, and where diagnoses are based on precise biomolecular events observed in real time.

1.
Bonomini V: Rene e paziente nella nefrologia del nuovo millennio. G Ital Nefrol, in press.
2.
Glassock RJ: American nephrology in 2010: Perspectives for its 50th anniversary. Am J Kidney Dis 1997;29:633–640.
3.
Holley JL: Nephrologists as primary care providers: A preview of the issues. Am J Kidney Dis 1998;31:574–583.
4.
Kletke PR: The changing supply of renal physicians. Am J Kidney Dis 1997;29:781–792.
5.
Steinman TI: Managed care, capitation, and the future of nephrology. J Am Soc Nephrol 1997;8:1618–1623.
6.
Reeders ST, Zhou J: The molecular genetics of inherited renal disease; in Davison, Cameron, Grunfeld, et al (eds): Oxford Textbook of Clinical Nephrology. Oxford, Medicare Publications, 1998; pp 2375–2381.
7.
Lien YH, Lai L: Gene therapy for renal disease. Kidney Int 1997;52(suppl 61):85–88.
8.
Bonomini V: Scientific knowledge and clinical application in artificial organs: Philosophy and practice. Int J Artif Organs 1994;17:617–619.
9.
Bonomini V, Colì L, Scolari MP, Stefoni S: Structure of dialysis membranes and long-term clinical outcome. Am J Nephrol 1995;15:455–462.
10.
Bonomini V, Colì L, Feliciangeli G, Scolari MP: Biotechnology in profiled dialysis. Nephrol Dial Transplant 1996;11(suppl 8):63–67.
11.
Bonomini V: Future prospects: Is there a better way? Nephrol Dial Transplant 1995;10(suppl 10):57–59.
12.
Halloran PF: Rethinking immunosuppression in terms of redundant and nonredundant steps in the immune response. Transplant Proc 1996;28(suppl 1):11–18.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.